Choosing Appropriate Estimands in Clinical Trials

被引:0
|
作者
Ann-Kristin Leuchs
Jörg Zinserling
Andreas Brandt
Dorothee Wirtz
Norbert Benda
机构
[1] Federal Institute for Drugs and Medical Devices (BfArM),
关键词
clinical trials; estimands; efficacy; effectiveness; nonadherence; missing data;
D O I
暂无
中图分类号
学科分类号
摘要
Lack of adherence to study protocol and missing data are often unavoidable in clinical trials, and both increase the need to differentiate between the ideal treatment effect if the medication is taken as directed and the treatment effect in presence of the actual adherence pattern. In this regard, estimands have become the focus of attention. An estimand is simply that which is being estimated. In the context of treatment benefit, an estimand may address either efficacy or effectiveness aspects. Defining the estimand of interest is an essential step to take before deciding on trial design and primary analysis. The choice of estimand has consequences for various other factors to be considered during any clinical trial’s planning phase. This study presents a process chart including all aspects to consider during planning. After deciding on the primary estimand, the trial design should be specified, followed by the primary analysis. Both should appropriately address the chosen estimand. Finally, sensitivity analyses should be taken into account. Provided are suggestions for all the planning steps involved, especially on choosing between efficacy and effectiveness, and relevant examples from clinical practice to illustrate them. It is recommended that one bear in mind the process chart during planning of any clinical trial and give reasonable justification for each decision in the study protocol.
引用
下载
收藏
页码:584 / 592
页数:8
相关论文
共 50 条
  • [21] Estimands-A Basic Element for Clinical Trials
    Pohl, Moritz
    Baumann, Lukas
    Behnisch, Rouven
    Kirchner, Marietta
    Krisam, Johannes
    Sander, Anja
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2021, 118 (51-52): : 883 - +
  • [22] Current Practices in Choosing Estimands and Sensitivity Analyses in Clinical Trials: Results of the ICH E9 Survey
    C. Fletcher
    S. Tsuchiya
    D. V. Mehrotra
    Therapeutic Innovation & Regulatory Science, 2017, 51 : 69 - 76
  • [23] Estimands in cluster-randomized trials: choosing analyses that answer the right question
    Kahan, Brennan C.
    Li, Fan
    Copas, Andrew J.
    Harhay, Michael O.
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2023, 52 (01) : 107 - +
  • [24] Ethics in musculoskeletal regenerative medicine; guidance in choosing the appropriate comparator in clinical trials
    de Windt, T. S.
    Niemansburg, S. L.
    Vonk, L. A.
    van Delden, J. M.
    Roes, K. C. B.
    Dhert, W. J. A.
    Saris, D. B. F.
    Bredenoord, A. L.
    OSTEOARTHRITIS AND CARTILAGE, 2019, 27 (01) : 34 - 40
  • [25] Principles for Defining Estimands in Clinical Trials-A Proposal
    Mutze, Tobias
    Bell, James
    Englert, Stefan
    Hougaard, Philip
    Jackson, Dan
    Lanius, Vivian
    Ravn, Henrik
    PHARMACEUTICAL STATISTICS, 2024,
  • [26] Comments on "A taxonomy of estimands for regulatory clinical trials with discontinuations"
    Doi, Masaaki
    Watanabe, Daisuke
    Takenouchi, Kazumasa
    Tsuchikawa, Masaru
    STATISTICS IN MEDICINE, 2017, 36 (27) : 4414 - 4416
  • [27] Planning and analyzing clinical trials with competing risks: Recommendations for choosing appropriate statistical methodology
    Poythress, J. C.
    Lee, Misun Yu
    Young, James
    PHARMACEUTICAL STATISTICS, 2020, 19 (01) : 4 - 21
  • [28] Estimands for factorial trials
    Kahan, Brennan C.
    Morris, Tim P.
    Goulao, Beatriz
    Carpenter, James
    STATISTICS IN MEDICINE, 2022, 41 (22) : 4299 - 4310
  • [29] Seeking harmony: estimands and sensitivity analyses for confirmatory clinical trials
    Mehrotra, Devan V.
    Hemmings, Robert J.
    Russek-Cohen, Estelle
    CLINICAL TRIALS, 2016, 13 (04) : 456 - 458
  • [30] Why estimands are needed to define treatment effects in clinical trials
    Oliver N. Keene
    Helle Lynggaard
    Stefan Englert
    Vivian Lanius
    David Wright
    BMC Medicine, 21